M·CAM releases Patently Obvious® on Avago Technologies Suing Maxim Integrated Products

Date:  Wed, 2015-06-10

M·CAM releases Patently Obvious® on Avago Technologies Suing Maxim Integrated Products.

On April 23rd, 2015, Avago Technologies General IP (Singapore) PTE. LTD filed suit against Maxim Integrated Products, Inc. regarding their semiconductor devices. Avago claims that Maxim infringes on five patents (US 5,523,359; US 5,599,739; US 6,040,616; US 6,083,271; and US 6,194,323) when manufacturing its MAX6946, MAX2634, MAX7356, MAX17126, DS28E10, MAX1305, and other semiconductor products. Maxim had, for nearly two decades, licensed semiconductor technologies from LSI Corporation’s patent portfolio. The license to these technologies lapsed on December 31, 2011. Avago acquired LSI in 2014, and claims that Maxim has continued to benefit from the technologies represented by the LSI portfolio. These technologies broadly cover methods for improved integrated circuit fabrication and design, including hard mask etching, barrier layer treatment, and specifying multiple power domains.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® on Avago Technologies Suing Maxim Integrated Products can be found HERE.

Celgene’s Revlimid® Patents Do Not Withstand Review

M·CAM Inc. presents Mechanics of Consciousness and The Metamoney Artifact RVU, an exhibition by Dylan Korelich

Date:  Tue, 2015-04-21

Mechanics of Consciousness and The Metamoney Artifact RVU April 21, 2015 – May 24, 2015

M·CAM Inc. is pleased to present Mechanics of Consciousness and The Metamoney Artifact RVU, an exhibition by Dylan Korelich. This series of oil paintings explores and continues the dialog between art, religion, science and esoteric symbolism. It is a narrative that employs the aesthetics and techniques of the old masters and the argument of form presented in modern abstract painting. The impulse is to revisit the questions of rationalism and empiricism in the dawn of a world where the artifact maybe reduced to a coded reconstruction in brain computer interface technology (BCI) and augmented reality applications. It questions what does it mean to be conscious? How do we form our values? And is it possible to capture our experience through the lens of an objective observer?

The Metamoney Artifact RVU is working symbol and it’s memory of transaction are a testament to a working model of value exchange using the principles of Integral Accounting. Rather than denominating an impulse to conclude and thereby terminate a relationship between transacting parties, it serves as a token of remembrance of the provision and receipt of value. As it can fulfill this function in any environment for any purpose, the RVU has placed the responsibility of stewardship and remembrance on all parties engaging with it.

To read more about the exhibition, Click HERE

M·CAM Chairman Dr. David Martin Feautured on Last Week Tonight with John Oliver

Date:  Mon, 2015-04-20

CHARLOTTESVILLE, VA April 20, 2015- M·CAM Chairman Dr. David Martin Featured on Last Week Tonight with John Oliver

Last Week Tonight with John Oliver featured M·CAM Chairman, Dr. David Martin, on a segment discussing patent trolls and patent troll reform legislation on April 19, 2015. The video featured Dr. Martin discussing the failure of the Innovation Act (H.R. 3309) in the United States Senate on Bloomberg West which originally aired May 23, 2014. In the clip, Cory Johnson asks Dr. Martin, “What do you make of this bill getting killed?” Dr. Martin responds, “Well, I know this is news but trial lawyers’ influence in Washington is alive and well.”

M·CAM releases Patently Obvious® on Potential Impairments to the Nokia Acquisition of Alcatel-Lucent

Date:  Thu, 2015-04-16

CHARLOTTESVILLE, VA April 16, 2015- M·CAM released its Patently Obvious® on Potential Impairments to the Nokia Acquisition of Alcatel-Lucent

On April 15, 2015, it was announced Nokia (NOK) plans to acquire Alcatel-Lucent (ALU). Despite market excitement that NOK will become a networking giant big enough to take on Ericsson, M&A enthusiasts have overlooked one glaring detail: part of ALU’s technology is restricted from transfer without the express consent of the U.S. Government’s security agencies, including parts of its patent portfolio.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® on potential impairments to the Nokia acquisition of Alcatel-Lucent can be found HERE.

M·CAM releases Patently Obvious® on the PTAB Review of Allergan Patents

Date:  Fri, 2015-04-10

CHARLOTTESVILLE, VA April 10, 2015- M·CAM released its Patently Obvious® on the PTAB Review of Allergan Patents.

Multinational pharmaceutical firm Allergan is facing a patent review challenge before the USPTO’s Patent Trial and Appeal Board (PTAB). The inter partes review (IPR), brought by New York-based hedge fund Ferrum Ferro Capital, challenges the validity of one of Allergan’s patents that protects the glaucoma drug Combigan®. As we reported in our last Patently Obvious®, released on March 19, this and other IPR cases are being brought as part of a new investment strategy that aims to profit from patent invalidations against large pharmaceutical companies.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® report on the PTAB Review of Allergan Patents can be found HERE.

M·CAM Chairman Dr. David Martin Scheduled on Film Panel at the RiverRun International Film Festival Screening of The Patent Wars

Date:  Wed, 2015-04-08

Dr. David Martin will be on a panel to discuss The Patent Wars after the screening of the film on April 22 in Winston Salem NC. The RiverRun International Film Festival has curated 74 feature films and 91 short films for the 2015 festival. Together with Producer Volker Ulrich, he will be discussing the documentary film written and directed by Hannah Leonie Prinzler which has been awarded Prêmio do Júri – Melhor Documentário at the International Film Festival in Sao Paulo, Brazil, and has been selected for Prix Europa, Mill Valley Film Festival, Starz Denver Film Festival, Marda Loop Justice Film Festival.

For tickets: https://uncsa.secure.force.com/ticket/#sections_a0FF000000JAtM6MAL

M·CAM Releases Quick Look Report on Cytec Industries

Date:  Mon, 2015-03-30

CHARLOTTESVILLE, VA March 30, 2015- M-CAM Releases Quick Look Report on Cytec Industries

“Compared to its competitors, DOW, DD,and HXL, CYT’s innovation seems fairly weak. DOW’s and DD’s innovation on mining chemicals has tighter market controls than CYT’s In Process Separation segment. CYT’s portfolio is also aging at a rapid pace and it is lacking patent coverage in key markets, including Brazil, China, and India, where spending is increasing in mining and defense. It is vital that CYT improves its proprietary controls in these markets in order to control pricing and keep margins strong.”

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The Quick Look report on Cytec Industries can be found HERE.

M·CAM IP Advisory Role Included in Exide Technologies Plan to Emerge from Chapter 11

Date:  Mon, 2015-03-30

M·CAM is pleased with the confirmation of the Plan of Reorganization approved in the United States Bankruptcy Court for the District of Delaware on March 27, 2015 by the Honorable Kevin J. Carey (Case No. 13-11482). This plan includes direct reference to the important work that M·CAM has conducted over the past year highlighting the considerable opportunities afforded by Exide’s extensive IP and intangible asset estate. In section 6.18 of the approved plan, M·CAM’s involvement is confirmed to “pursue monetization of intellectual property through offset or similar transactions that are identified by the Reorganized Debtor.” http://www.exiderestructuringinfo.com/pdflib/3423_11482.pdf

Kodak’s Market Conviction on its IP Portfolio Inspires New York Times Article

Date:  Mon, 2015-03-23

On Sunday March 22, 2015, the New York Times published an article on Kodak’s IP Portfolio. Kodak’s strong conviction on the high value of its patent portfolio and its plans for monetization generated interest in the article.

The full story can be found HERE.

Dr. David Martin and The Unstoppables featured on the cover of CEO Magazine.

Date:  Fri, 2015-03-20

On 25 January 2015, the future of Australian business changed. The country’s sharpest entrepreneurs, investors, and business leaders embarked on a powerful journey to the Earth’s southernmost continent, Antarctica. They were boldly dubbed the ”˜Unstoppables’.

Unstoppables An Ecosystem for Entrepreneurs. Brazilian self-made millionaire Julio De Laffitte founded the Unstoppables movement with the aim to raise the financial intelligence of Australia and ignite entrepreneurial spirit. He worked closely with co-founder and project director Priscila Duarte to encourage more than 100 elite business brains from a diverse range of sectors to travel to one of the harshest yet most beautiful and awe-inspiring places in the world for an 11-day think tank.

The location ensured attendees, including myself, were removed from daily distractions, allowing networking between savvy entrepreneurs, millionaire business leaders, and industry heavyweights and inspiring radical thinking. We participated in a series of workshops hosted by top-flight facilitators and corporate leaders to foster fresh concepts and come back with the energy to ultimately shape the future of Australian business.

Similar to the Australian business environment, it wasn’t long before we were required to adapt. Mother Nature had thrown us a curve ball, delaying our adventure by several days due to poor weather; however, we showed resilience and persistence to finally achieve our goal and get to our destination. These qualities, and everything else we were to discover and take in, would prove to be just as relevant to our professional spheres back home as they were in Antarctica. – See more at: http://www.theceomagazine.com.au/news/ecosystem-entrepreneurs.html#sthas…

Dr. Martin to Address the Islamic Food and Nutrition Council of America 17th International Halal Food Conference in Chicago.

Date:  Fri, 2015-03-20

M·CAM Chairman Dr. David E. Martin will deliver a keynote address on Islamic Finance and Global Trade at the 17th International Halal Food Conference April 13-15 in Schaumburg, Illinois. Dr. Martin has been an Advisory Board member of the U.S. Halal Association for several years and has advocated for multi-lateral dialogue and engagement on Halal finance and trade in the global market. Recognizing the principles of ethical commercial and social engagement, Dr. Martin will address the importance of integrity, transparency, and mutual benefit linked to productivity as the cornerstone to develop robust business around the world.

M·CAM Releases Patently Obvious® on The Financial Uncertainties of Patent Rules Changes

Date:  Thu, 2015-03-19

CHARLOTTESVILLE, VA March 19, 2015- M·CAM released its Patently Obvious® on The Financial Uncertainties of Patent Rules Changes.

The Leahy-Smith America Invents Act, Public Law 112-29, provides a series of new post-grant challenges to patent validity and enforcement. A series of material rulings from the United States Supreme Court over the past five years that narrow the scope of patentable subject matter and expand the grounds of patent claims rejections for obviousness have directly impacted the patent approval process. Inter Partes Review, Covered Business Method patent review, and new methods of Post-Grant Review, which comprise new jurisdiction for the Patent Trial and Appeal Board (PTAB), are dramatically altering the allowance of patentable inventions in the United States.

One company that is attempting to capitalize on these new avenues for post-grant patent review is Dallas’ Hayman Capital Management. In February, The New York Times reported that the hedge fund is specifically targeting large pharmaceutical companies with a combined market capitalization of $450 billion for Inter Partes Review based on patent obviousness. Hayman founder Kyle Bass was quoted in a report by Reuters as saying that Hayman’s strategy is “”¦to challenge and invalidate patents through the IPR process … (and) we are not going to settle.”

Hayman and other investors seem to believe that pharmaceuticals are the industry most impacted by the changes to PTAB review provided for under the America Invents Act. M·CAM’s Patently Obvious report demonstrates that there is in fact a much broader set of impacts across a variety of sectors. M·CAM measures precisely which companies are being hit with patentability rejections and subsequently have adverse cashflow effects. These measurements demonstrate an unconsidered effect on markets which may be used to advantageously predict the reduction or loss of proprietary cashflows and erosion of competitive positions.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® report on The Financial Uncertainties of Patent Rules Changes can be found HERE.